Search

Guselkumab is an anti-interleukin-23 monoclonal antibody that is approved for plaque psoriasis and psoriatic arthritis. We present a case of a 28-year-old female patient with acute onset of guttate psoriasis after a blistering sunburn. She had no personal or family history of psoriasis or chronic inflammatory skin disease. The guttate psoriasis was refractory to topical treatment. After the first dose of guselkumab (100 mg subcutaneous injection), the patient experienced near-clearance of her guttate psoriasis, with continued improvement and drug-free remission 8 months after cessation of treatment. Dermatologists could consider guselkumab as a treatment option for patients with guttate psoriasis. Future studies should examine the potential for guselkumab to induce drug-free remissions in guttate psoriasis.

In this study, we performed a patch test by applying Bariderm Shield Cream MD in patients with facial dermatitis or sensitive skin with weakened skin barrier function and investigated whether it had an effect in relieving clinical symptoms and improving skin barrier function. We also want to find out the safety of whether new dermatitis will not occur. Methods: 15 pruritus patients (average age 33.07 ± 11.57) applied this twice daily for 8 weeks. Effectiveness was evaluated using SS-10 (Sensitive scale-10), severity by area, TEWL (transepidermal water loss), and SCH (skin corneum hydration). We performed repeated measures ANOVA and post hoc analysis using Python statistics. Results: Fifteen pruritus patients (average age 33.07 ± 11.57) applied this twice daily for 8 weeks. Effectiveness was evaluated using SS-10 (Sensitive scale-10), severity by area, TEWL (transepidermal water loss), and SCH (skin corneum hydration). SS-10 showed a significant difference at week 8. TEWL decreased after 8 weeks, while moisture increased after 4 weeks of application. Severity scores for erythema, scales, papules, and pustules on both cheeks notably decreased compared to baseline at week 4 and 8 after application. Conclusion: This study shows that Barriederm Shield Cream MD® is safe for patients with sensitive skin. It suggests that it is suitable for sensitive skin, with the result of improving the skin barrier, and addresses safety and efficacy issues. [ABSTRACT FROM AUTHOR]

Purpose: Vitiligo is a disease of acquired depigmentation characterized by the destruction of melanocytes. A theoretical association between low level of 25‐hydroxyvitamin D [25(OH)D] and vitiligo has been previously suggested. The objective of this study was to determine the efficacy of intramuscular injection of cholecalciferol with excimer laser compared with the excimer laser alone for vitiligo treatment. Methods: This study included 26 patients diagnosed with non‐segmental vitiligo and low serum 25(OH)D levels (<20 ng/mL). The participants were randomly divided into two groups through randomization. The treatment using a 308‐nm excimer laser was administered to both groups, and the study group additionally received cholecalciferol injection. Results: The Vitiligo Area Scoring Index (VASI) scores showed an 83.6% improvement over the initial score in the study group, whereas the control group showed a 54.7% improvement after 6 months of treatment. After 6 months of treatment, the study group showed a significantly higher proportion of patients who achieved VASI50 and VASI75 compared with the control group. Conclusion: Intramuscular injection of cholecalciferol can be a supplemental option for the treatment of vitiligo patients with vitamin D deficiency with excimer laser therapy. [ABSTRACT FROM AUTHOR]

This article discusses the role of the transient receptor potential vanilloid-3 (TRPV3) channel in inducing thymic interstitial lymphopoietin (TSLP) and its implications for itch pathways. The study found that TRPV3 activation regulates TSLP expression through calcium influx and the calcineurin/NFAT/NF-kB pathway. Carvacrol, a compound that activates TRPV3, was shown to increase TSLP and calcium influx, suggesting its involvement in TRPV3-mediated itch pathways. The findings provide insights into the molecular mechanisms of chronic pruritus and potential therapeutic targets for inflammatory skin diseases. [Extracted from the article]

Particulate matter (PM2.5) is an environmental pollutant causing skin inflammatory diseases via epidermal barrier damage. However, the mechanism and related gene expression induced by PM2.5 remains unclear. Our aim was to determine the effect of PM2.5 on human skin tissue ex vivo, and elucidate the mechanism of T helper 17 cell‐related inflammatory cytokine and skin barrier function. We verified the expression levels of gene in PM2.5‐treated human skin tissue using Quantseq (3′ mRNA‐Seq), and Gene Ontology (GO) terms and protein–protein interaction (PPI) networks were performed. The PM2.5 treatment significantly enhanced the expression of Th 1, 2, 17 and 22 cell‐related genes (cut‐off value: │1.2 │ > fold change and p < 0.05). Most of all, Th17 cell‐related genes are upregulated and those genes are associated with skin epidermal barrier function and Aryl hydrocarbon receptor (AhR), a xenobiotic receptor, pathway. In human keratinocyte cell lines, AhR‐regulated genes (e.g. AhRR, CYP1A1, IL6 and IL36G), Th17 cell‐related genes (e.g. IL17C) and epidermal barrier–related genes (e.g. SPRR2A and KRT71) are significantly increased after PM2.5. In the protein level, the secretion of IL‐6 and IL‐36G was increased in human skin tissue following PM2.5 treatment, and the expression of SPRR2A and KRT71 was significantly increased. PM2.5 exposure could ruin the skin epidermal barrier function via AhR‐ and Th17 cell‐related inflammatory pathway. [ABSTRACT FROM AUTHOR]